Cover Image
市場調查報告書

多發性骨髓瘤:現在·未來的主要企業

Multiple Myeloma - Current and Future Players

出版商 GlobalData 商品編碼 368822
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
多發性骨髓瘤:現在·未來的主要企業 Multiple Myeloma - Current and Future Players
出版日期: 2015年11月01日 內容資訊: 英文 83 Pages
簡介

本報告涵括正在急速成長中的多發性骨髓瘤治療藥市場,以包含新加入廠商的競爭情形為焦點,提供主要企業最新資訊等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 市場預測

  • 全球市場
    • 預測
    • 推動因素 - 全球問題點
    • 障礙 - 全球問題點

第4章 現在·未來的主要企業

  • 概要與企業策略趨勢
  • 企業簡介
    • Millennium Pharmaceuticals/武田藥品工業
    • Celgene
    • Onyx Pharmaceuticals/Amgen
    • Novartis
    • AbbVie
    • Bristol-Myers Squibb
    • Janssen

第5章 附錄

圖表

目錄
Product Code: GDHC1051FPR

GlobalData has released its pharma report, "Multiple Myeloma - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Multiple Myeloma Market. The report identifies and analyses the key companies shaping and driving the global Multiple Myeloma market. The report provides insight into the competitive Multiple Myeloma landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Multiple Myeloma
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Multiple Myeloma sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Multiple Myeloma market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Multiple Myeloma market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers - Global Issues
    • 3.1.3. Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview and Trends in Corporate Strategy
  • 4.2. Company Profiles
    • 4.2.1. Millennium Pharmaceuticals/Takeda
    • 4.2.2. Celgene
    • 4.2.3. Onyx Pharmaceuticals/Amgen
    • 4.2.4. Novartis
    • 4.2.5. AbbVie
    • 4.2.6. Bristol-Myers Squibb
    • 4.2.7. Janssen

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed Multiple Myeloma Patients
    • 5.4.2. Percent of Drug-Treated Patients
    • 5.4.3. Drugs Included in Each Therapeutic Class
    • 5.4.4. Launch and Patent Expiry Dates
    • 5.4.5. General Pricing Assumptions
    • 5.4.6. Individual Drug Assumptions
    • 5.4.7. Pricing of Pipeline Agents
    • 5.4.8. Generic Erosion
  • 5.5. Primary Research - KOLs Interviewed for this Report
  • 5.6. Primary Research - High-Prescriber Survey
  • 5.7. About the Authors
    • 5.7.1. Analyst
    • 5.7.2. Therapy Director
    • 5.7.3. Epidemiologist
    • 5.7.4. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Disclaimer

List of Tables

  • Table 1: Annual Global Sales ($m) for Multiple Myeloma by Region, 2013-2023
  • Table 2: Annual Global Sales ($m) for Multiple Myeloma by Drug, 2013-2023
  • Table 3: Global Multiple Multiple Myeloma - Drivers, 2013-2023
  • Table 4: Global Multiple Multiple Myeloma - Barriers, 2013-2023
  • Table 5: Key Companies in the Multiple Myeloma Market Across the 8MM, 2013-2023
  • Table 6: Millennium Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 7: Celgene's Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 8: Onyx Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 9: Novartis' Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 10: AbbVie's Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 11: BMS' Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 12: Janssen's Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 13: Multiple Myeloma Diagnosed Incidence, 2013-2023
  • Table 14: Multiple Myeloma Drugs and Pipeline agents, Launch Dates
  • Table 15: Multiple Myeloma Drugs and Pipeline agents, Anticipated Patent Expiries
  • Table 16: Average Cost of Therapy for Velcade
  • Table 17: Average Duration of Treatment (Weeks) for Velcade
  • Table 18: Average Cost of Therapy for Kyprolis ($)
  • Table 19: Average Duration of Treatment (Weeks) for Kyprolis
  • Table 20: Average Cost of Therapy for Revlimid ($)
  • Table 21: Average Duration of Treatment (Weeks) for Revlimid
  • Table 22: Average Cost of Therapy for Pomalyst/Imnovid ($)
  • Table 23 Average Duration of Treatment (Weeks) for Pomalyst/Imnovid
  • Table 24: Average Cost of Therapy for Farydak ($)
  • Table 25: Duration of Treatment (Weeks) for Farydak
  • Table 26: Average Cost of Therapy for Ixazomib ($)
  • Table 27: Duration of Treatment (Weeks) for Ixazomib
  • Table 28: Average Cost of Therapy for Empliciti ($)
  • Table 29: Duration of Treatment (Weeks) for Empliciti
  • Table 30: Average Cost of Therapy for Daratumumab ($)
  • Table 31: Duration of Treatment (Weeks) for Daratumumab
  • Table 32: Average Cost of Therapy for Daratumumab ($)
  • Table 33: Duration of Treatment (Weeks) for Daratumumab
  • Table 34: Numbers of Prescribers Surveyed in Each Country

List of Figures

  • Figure 1: Annual Global Sales for Multiple Myeloma by Region, 2013-2023
  • Figure 2: Annual Global Sales for Multiple Myeloma by Region - 2013, 2023
  • Figure 3: Annual Global Sales for Multiple Myeloma by Drug, 2013-2023
  • Figure 4: Global Sales for Multiple Myeloma by Drug, 2013 - 2023
  • Figure 5: Global Sales ($m) of Branded Products for Multiple Myeloma by Company, 2013 - 2023
  • Figure 6: Company Portfolio Gap Analysis in Multiple Myeloma, 2013-2023
Back to Top